Generation and neutralization of pseudovirions of human papillomavirus type 33 - PubMed (original) (raw)

Generation and neutralization of pseudovirions of human papillomavirus type 33

F Unckell et al. J Virol. 1997 Apr.

Abstract

Since human papillomaviruses (HPV) cannot be propagated in cell culture, the generation of infectious virions in vitro is a highly desirable goal. Here we report that pseudovirions can be generated by the assembly of virus-like particles (VLPs) in COS-7 cells containing multiple copies of a marker plasmid. Using recombinant vaccinia viruses, we have obtained spherical VLPs of HPV type 33 (HPV-33) which fractionate into heavy and light VLPs in cesium chloride density gradients. VLPs in the heavy fraction (1.31 g/cm3) carry the plasmid in DNase-resistant form and are capable of transferring the genetic marker located on the plasmid to COS-7 cells in a DNase-resistant way (pseudoinfection). The minor capsid protein L2 is not required for encapsidation but is essential for efficient pseudoinfection. Antiserum to HPV-33 VLPs inhibits VLP-mediated DNA transfer with high efficiency. Antisera to VLPs of HPV-18 and HPV-16 are not neutralizing, although the HPV-16 antiserum exhibited some cross-reactivity with HPV-33 VLPs in an enzyme-linked immunosorbent assay. In a cell binding assay, the titer of the HPV-33 VLP antiserum was 1:200 compared to the neutralization titer of 1:10(5). This indicates that neutralization is essentially due to the inhibition of cellular processes after VLP binding to cells. The encapsidation of marker plasmids into VLPs provides a sensitive and fast assay for the evaluation of neutralizing potentials of antisera against papillomavirus infections.

PubMed Disclaimer

Similar articles

• Immunological analyses of human papillomavirus capsids.
  Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck RE, Rose RC. Giroglou T, et al. Vaccine. 2001 Feb 8;19(13-14):1783-93. doi: 10.1016/s0264-410x(00)00370-4. Vaccine. 2001. PMID: 11166904
• Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles.
  Xu Y, Wang Q, Han Y, Song G, Xu X. Xu Y, et al. J Med Microbiol. 2007 Jul;56(Pt 7):907-913. doi: 10.1099/jmm.0.47073-0. J Med Microbiol. 2007. PMID: 17577054
• Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
  Boxus M, Fochesato M, Miseur A, Mertens E, Dendouga N, Brendle S, Balogh KK, Christensen ND, Giannini SL. Boxus M, et al. J Virol. 2016 Jun 24;90(14):6314-25. doi: 10.1128/JVI.00449-16. Print 2016 Jul 15. J Virol. 2016. PMID: 27147749 Free PMC article.
• Papillomavirus-like particle vaccines.
  Schiller JT, Lowy DR. Schiller JT, et al. J Natl Cancer Inst Monogr. 2001;(28):50-4. doi: 10.1093/oxfordjournals.jncimonographs.a024258. J Natl Cancer Inst Monogr. 2001. PMID: 11158207 Review.
• Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
  Stanley M, Lowy DR, Frazer I. Stanley M, et al. Vaccine. 2006 Aug 31;24 Suppl 3:S3/106-13. doi: 10.1016/j.vaccine.2006.05.110. Epub 2006 Jun 23. Vaccine. 2006. PMID: 16949996 Review.

Cited by

• Proteoglycans in host-pathogen interactions: molecular mechanisms and therapeutic implications.
  Bartlett AH, Park PW. Bartlett AH, et al. Expert Rev Mol Med. 2010 Feb 1;12:e5. doi: 10.1017/S1462399409001367. Expert Rev Mol Med. 2010. PMID: 20113533 Free PMC article. Review.
• In vitro construction of pseudovirions of human papillomavirus type 16: incorporation of plasmid DNA into reassembled L1/L2 capsids.
  Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T. Kawana K, et al. J Virol. 1998 Dec;72(12):10298-300. doi: 10.1128/JVI.72.12.10298-10300.1998. J Virol. 1998. PMID: 9811779 Free PMC article.
• L1 Recombinant Proteins of HPV Tested for Antibody Forming Using Sera of HPV Quadrivalent Vaccine.
  Akuzum B, Kim S, Nguyen TT, Hong J, Lee S, Kim E, Kim J, Choi Y, Jhun H, Lee Y, Kim H, Sohn DH, Kim S. Akuzum B, et al. Immune Netw. 2018 Jun 4;18(3):e19. doi: 10.4110/in.2018.18.e19. eCollection 2018 Jun. Immune Netw. 2018. PMID: 29984037 Free PMC article.
• Bovine papillomavirus type 1 infection is mediated by SNARE syntaxin 18.
  Laniosz V, Nguyen KC, Meneses PI. Laniosz V, et al. J Virol. 2007 Jul;81(14):7435-48. doi: 10.1128/JVI.00571-07. Epub 2007 May 2. J Virol. 2007. PMID: 17475643 Free PMC article.
• Viral entry mechanisms: human papillomavirus and a long journey from extracellular matrix to the nucleus.
  Sapp M, Bienkowska-Haba M. Sapp M, et al. FEBS J. 2009 Dec;276(24):7206-16. doi: 10.1111/j.1742-4658.2009.07400.x. FEBS J. 2009. PMID: 19878308 Free PMC article. Review.

References

1. 1. J Virol. 1996 May;70(5):3298-301 - PubMed
2. 1. J Gen Virol. 1995 Nov;76 ( Pt 11):2661-7 - PubMed
3. 1. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463-7 - PubMed
4. 1. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 - PubMed
5. 1. Virology. 1980 Jun;103(2):369-75 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database